瑞思迈

最新新闻

• Stifel Maintains ResMed(RMD.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• 公司公告
  8-K: Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026
  SEC · 2025/10/31
• 公司公告
  ResMed Inc: LR 1.15.3 Compliance
  ASX · 2026/8/28
• Citi Maintains ResMed(RMD.US) With Hold Rating, Raises Target Price to $240
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  Rothschild & Co Redburn Initiates ResMed(RMD.US) With Hold Rating, Announces Target Price $230
  \u5e02\u573a\u8d44\u8baf · 2026/8/19
• 公司公告
  8-K: Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
  SEC · 2026/5/1
• 评级变动
  Ord Minnett Remains a Buy on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
  TipRanks · 2026/8/10
• RBC Capital Upgrades ResMed(RMD.US) to Buy Rating, Raises Target Price to $262
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 评级变动
  Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD) Gets a Buy From Canaccord Genuity
  TipRanks · 2026/9/29
• KeyBanc Maintains ResMed(RMD.US) With Buy Rating, Raises Target Price to $267
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 公司公告
  8-K: Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
  SEC · 2026/8/7
• 评级变动
  Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD) Receives a Buy From Ord Minnett
  TipRanks · 2026/10/5
• 公司公告
  8-K: Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
  SEC · 2026/1/30
• 评级变动
  Macquarie Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
  TipRanks · 2026/8/10
• 评级变动
  J.P. Morgan Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
  TipRanks · 2026/8/12
• 评级变动
  Jarden Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
  TipRanks · 2026/8/12
• 评级变动
  Mizuho Securities Maintains ResMed(RMD.US) With Buy Rating, Raises Target Price to $235
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Citi Sticks to Their Hold Rating for Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
  TipRanks · 2026/9/10
• 评级变动
  Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD) Gets a Hold From Citi
  TipRanks · 2026/9/24
• Stifel Maintains ResMed(RMD.US) With Hold Rating, Announces Target Price $235
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like. -- Barrons.com
  Barron's · 2026/9/16
• 评级变动
  ResMed Price Target Raised 0.4% to A$46.80/Share by Macquarie
  Dow Jones · 2026/8/10

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。